Amicus Therapeutics PE Ratio 2010-2022 | FOLD

Current and historical p/e ratio for Amicus Therapeutics (FOLD) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Amicus Therapeutics PE ratio as of January 26, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Amicus Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-01-27 12.83 0.00
2022-09-30 10.44 $-0.92 0.00
2022-06-30 10.74 $-0.99 0.00
2022-03-31 9.47 $-0.97 0.00
2021-12-31 11.55 $-0.92 0.00
2021-09-30 9.55 $-0.90 0.00
2021-06-30 9.64 $-0.96 0.00
2021-03-31 9.88 $-0.97 0.00
2020-12-31 23.09 $-1.07 0.00
2020-09-30 14.12 $-1.15 0.00
2020-06-30 15.08 $-1.14 0.00
2020-03-31 9.24 $-1.30 0.00
2019-12-31 9.74 $-1.51 0.00
2019-09-30 8.02 $-1.57 0.00
2019-06-30 12.48 $-2.17 0.00
2019-03-31 13.60 $-2.14 0.00
2018-12-31 9.58 $-1.86 0.00
2018-09-30 12.09 $-1.86 0.00
2018-06-30 15.62 $-1.71 0.00
2018-03-31 15.04 $-1.72 0.00
2017-12-31 14.39 $-1.83 0.00
2017-09-30 15.08 $-1.83 0.00
2017-06-30 10.07 $-1.47 0.00
2017-03-31 7.13 $-1.53 0.00
2016-12-31 4.97 $-1.49 0.00
2016-09-30 7.40 $-1.43 0.00
2016-06-30 5.46 $-1.42 0.00
2016-03-31 8.45 $-1.29 0.00
2015-12-31 9.70 $-1.19 0.00
2015-09-30 14.01 $-1.08 0.00
2015-06-30 14.15 $-0.98 0.00
2015-03-31 10.88 $-0.93 0.00
2014-12-31 8.32 $-0.93 0.00
2014-09-30 5.95 $-0.91 0.00
2014-06-30 3.34 $-0.98 0.00
2014-03-31 2.07 $-1.07 0.00
2013-12-31 2.35 $-1.17 0.00
2013-09-30 2.32 $-1.15 0.00
2013-06-30 2.33 $-1.20 0.00
2013-03-31 3.17 $-1.09 0.00
2012-12-31 2.68 $-1.09 0.00
2012-09-30 5.20 $-0.64 0.00
2012-06-30 5.50 $-0.58 0.00
2012-03-31 5.28 $-0.75 0.00
2011-12-31 3.44 $-0.79 0.00
2011-09-30 3.84 $-1.52 0.00
2011-06-30 5.94 $-1.80 0.00
2011-03-31 7.09 $-1.84 0.00
2010-12-31 4.70 $-1.99 0.00
2010-09-30 3.92 $-0.06 0.00
2010-06-30 2.24 $-0.09 0.00
2010-03-31 3.19 $-0.28 0.00
2009-12-31 3.97 $-0.29 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.700B $0.306B
Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00